Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
A0A5B9
UPID:
TRBC2_HUMAN
Alternative names:
-
Alternative UPACC:
A0A5B9; A0A075B6S1
Background:
The T cell receptor beta constant 2 plays a pivotal role in the immune response, being integral to the function of T lymphocytes. It recognizes peptide-major histocompatibility complexes, initiating a cascade of intracellular events critical for T cell activation and differentiation.
Therapeutic significance:
Understanding the role of T cell receptor beta constant 2 could open doors to potential therapeutic strategies, particularly in modulating immune responses and developing treatments for immune-related disorders.